Rapid Therapeutic Science Laboratories, Inc.
RTSL · OTC
12/31/2024 | 12/31/2022 | 12/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.06 | 0.00 | 0.00 |
| FCF Yield | 0.00% | -20.50% | -131.16% | -776.39% |
| EV / EBITDA | -58.70 | -7.78 | -1.75 | -6.65 |
| Quality | ||||
| ROIC | -22.97% | -173.00% | -526.14% | 118.44% |
| Gross Margin | 0.00% | 0.00% | 62.55% | 21.71% |
| Cash Conversion Ratio | 0.64 | 0.77 | 0.31 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | – |
| Free Cash Flow Growth | 0.00% | 52.40% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -58.18 | -3.09 | -0.85 | -6.45 |
| Interest Coverage | -0.83 | -0.67 | -1.64 | -0.94 |
| Efficiency | ||||
| Inventory Turnover | 0.14 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -567.54 | 0.00 | -529,536.53 | -3,294.28 |